

# OVARIAN CANCER SYMPOSIUM

15, 18, 22 & 25 JUNE 2021



supported by  
**AstraZeneca** 

THE CHANGING WORLD OF OVARIAN CANCER TREATMENT

## Event program

### SESSION 1 | Tuesday 15<sup>th</sup> June • 7-9pm (AEST) • GENOMICS

Chair: TBC

- 7:00pm **Prof Ahmed Ahmed (Oxford, UK)**  
The Oxford Classic and the story of the “SPARC cluster”
- 7:40pm **A/Prof Kylie Gorringer**  
Mucinous ovarian cancer: genomics and post-genomics approaches
- 8:05pm **Dr Dale Garsed**  
The genomic landscape of high-grade serous ovarian cancer in long-term survivors
- 8:30pm **Prof Anna deFazio**  
INOVAte: Molecular Profiling of Ovarian Cancer for Clinical Trials and Individualising Treatment

### SESSION 2 | Friday 18<sup>th</sup> June • 9-11am (AEST) • IMMUNOTHERAPY & TARGETED THERAPY

Chair: TBC

- 9:00am **Dr Elise Kohn (Bethesda MD, US)**  
Not your average DNA damage: leveraging underlying DNA repair dysfunction for benefit
- 9:40am **Dr Elaine Sanij**  
Combination therapy of PARPi and CX-5461 in models of HGSC
- 10:20am **Dr Tarek Meniawy**  
Immunotherapy in ovarian cancer – progress and future directions

### SESSION 3 | Tuesday 22<sup>nd</sup> June • 7-9pm (AEST) • TUMOUR BOARD DISCUSSION

Chair: Prof Anna deFazio

- 7:00pm **Prof Charlie Gourley (Edinburgh, Scotland)**  
Molecular stratification of endometrioid ovarian carcinoma
- 7:40pm **Tumour Board Discussion Panel:**  
- Prof Anna deFazio  
- A/Prof Philip Beale  
- Dr Tania Moujaber  
- A/Prof Lyndal Anderson  
- A/Prof Alison Brand

### SESSION 4 | Friday 25<sup>th</sup> June • 9-11am (AEST) • PARP INHIBITORS

Chair: TBC

- 9:00am **Dr Kathleen Moore (Oklahoma, US)**  
Changes and challenges in the treatment paradigm for front line ovarian cancer
- 9:40am **A/Prof Clare Scott**  
Understanding HRD in HGSOC and its impact on treatment choice in early lines of therapy
- 10:20am **Dr Alan D'Andrea (Boston MA, US)**  
A first-in-class Polymerase Theta Inhibitor selectively targets Homologous Recombination-Deficient Tumors